David A. Siegel I Mab Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Mab stock. As of the latest transaction made, Two Sigma Advisers, LP holds 499,300 shares of IMAB stock, worth $479,328. This represents 0.0% of its overall portfolio holdings.

Number of Shares

499,300

Previous 576,600 13.41%

Holding current value

$479,328

Previous $962,000 35.65%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.03 - $1.72 $79,619 - $132,956	-77,300 Reduced 13.41%	499,300 $619,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $1.9 $63,990 - $76,950	-40,500 Reduced 6.56%	576,600 $962,000
Q1 2024 May 15, 2024	BUY	$1.54 - $2.37 $89,936 - $138,408	58,400 Added 10.45%	617,100 $1.15 Million
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.9 $178,112 - $279,680	147,200 Added 35.77%	558,700 $1.06 Million
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $113,516 - $294,372	96,200 Added 30.51%	411,500 $543,000
Q2 2023 Aug 14, 2023	BUY	$2.95 - $3.85 $202,960 - $264,880	68,800 Added 27.91%	315,300 $942,000
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $218,680 - $524,690	-71,000 Reduced 22.36%	246,500 $852,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $277,886 - $419,418	86,300 Added 37.33%	317,500 $1.33 Million
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $546,563 - $1.68 Million	136,300 Added 143.62%	231,200 $927,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $483,795 - $1.08 Million	-58,500 Reduced 38.14%	94,900 $1.07 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $1.92 Million - $7.2 Million	153,400 New	153,400 $2.49 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

15.5M

Call Options Held

56.4K

Put Options Held

5.8K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $79.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account